Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
Public ClinicalTrials.gov record NCT00741819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.
Study identification
- NCT ID
- NCT00741819
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 73 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Dec 2010 (Actual)
- Last update posted
- Feb 20, 2013
2008 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| UCSD Medical Center | La Jolla | California | 82037 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | — |
| Long Island Jewish Medical Center - North Shore | New Hyde Park | New York | 11040 | — |
| Beth Israel Medical Center | New York | New York | 10003-3314 | — |
| Cornell University Medical Center | New York | New York | 10021 | — |
| Columbia Presbyterian Medical Center | New York | New York | 10032 | — |
| Mary M. Parkes Center for Asthma, Allergy and Pulmonary Care | Rochester | New York | 14623 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburg Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00741819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00741819 live on ClinicalTrials.gov.